Expects 4Q Reported and Constant Currency Core Revenue Growth of ~4% Fiscal Year Reported and Constant Currency Core Revenue Growth of ~16% and ~15%, respectively RARITAN, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the “Company”), one of the

RARITAN, N.J., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics (IVD) companies, today announced that members of its management team are scheduled to participate in the 40 th Annual J.P.

Strategic, transformational acquisition advances Quidel’s global leadership in diagnostics Transaction Highlights Brings together highly complementary diagnostic portfolios with world-class technologies and platforms spanning high-throughput systems to near-patient and at-home testing.

RARITAN, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) --   Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics (IVD) companies, today announced that members of its management team are scheduled to participate in the 4 th Annual Evercore ISI HealthCONx

Strong Revenue Growth Drives Financial Results Company Raises Fiscal 2021 Guidance Across all Key Metrics Highlights   Third quarter revenue increased 15.8% to $522.5 million, or 14.3% in constant currency   Core revenue grew 14.8% to $508.9 million for the quarter, or 13.2% in constant currency  

RARITAN, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics companies, today announced it will report results for its third quarter 2021 ended October 3, 2021, after the market close on Wednesday,

Company receives top customer rating across six categories in the 2021 IMV ServiceTrak™ Awards RARITAN, N.J. , Sept. 27, 2021 /PRNewswire/ --  Ortho Clinical Diagnostics Holdings plc  (Nasdaq: OCDX) today announced that for the sixth consecutive year its Ortho Care™ Service and Support program was

New Menu Capability Now Available on VISION and VISION MAX Analyzers Increases Confidence in Blood Transfusion-Related Test Results RARITAN, N.J. , Sept. 27, 2021 /PRNewswire/ --  Ortho Clinical Diagnostics  (NASDAQ: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies,

RARITAN, N.J., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the “Company”), one of the world’s largest pure-play in vitro diagnostics companies, today announced the closing (the “Closing”) of the previously announced underwritten secondary offering of

RARITAN, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the “Company”), one of the world’s largest pure-play in vitro diagnostics companies, today announced the pricing of the previously announced underwritten secondary offering of 22,000,000 of the